Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.

N-glycosylation of immunoglobulin G (IgG) at asparigine residue 297 plays a critical role in antibody stability and immune cell-mediated Fc effector function. Current understanding pertaining to Fc glycosylation is based on studies with IgGs that are either fully glycosylated [both heavy chain (HC) glycosylated] or aglycosylated (neither HC glycosylated). No study has been reported on the properties of hemi-glycosylated IgGs, antibodies with asymmetrical glycosylation in the Fc region such that one HC is glycosylated and the other is aglycosylated. We report here for the first time a detailed study of how hemi-glycosylation affects the stability and functional activities of an IgG1 antibody, mAb-X, in comparison to its fully glycosylated counterpart. Our results show that hemi-glycosylation does not impact Fab-mediated antigen binding, nor does it impact neonatal Fc receptor binding. Hemi-glycosylated mAb-X has slightly decreased thermal stability in the CH2 domain and a moderate decrease (∼20%) in C1q binding. More importantly, the hemi-glycosylated form shows significantly decreased binding affinities toward all Fc gamma receptors (FcγRs) including the high-affinity FcγRI, and the low-affinity FcγRIIA, FcγRIIB, FcγRIIIA and FcγRIIIB. The decreased binding affinities to FcγRs result in a 3.5-fold decrease in antibody-dependent cell cytotoxicity (ADCC). As ADCC often plays an important role in therapeutic antibody efficacy, glycosylation status will not only affect the antibody quality but also may impact the biological function of the product.

[1]  Huijuan Li,et al.  Purification process development of a recombinant monoclonal antibody expressed in glycoengineered Pichia pastoris. , 2011, Protein expression and purification.

[2]  Pamela J. Bjorkman,et al.  Crystal structure of the complex of rat neonatal Fc receptor with Fc , 1994, Nature.

[3]  R. Rustandi,et al.  Applications of CE SDS gel in development of biopharmaceutical antibody‐based products , 2008, Electrophoresis.

[4]  Colleen E. Price,et al.  Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[5]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[6]  J. Ravetch,et al.  Antibodies, Fc receptors and cancer. , 2007, Current opinion in immunology.

[7]  R. Jefferis.  Glycosylation of Recombinant Antibody Therapeutics , 2008, Biotechnology progress.

[8]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Parren,et al.  Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. , 2008, Blood.

[10]  Youwei Jiang,et al.  Optimization of humanized IgGs in glycoengineered Pichia pastoris , 2006, Nature Biotechnology.

[11]  S L Morrison,et al.  Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1 , 1994, The Journal of experimental medicine.

[12]  S. Iida,et al.  The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation , 2008, Glycobiology.

[13]  J. Emtage,et al.  The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. , 1995, Immunology.

[14]  R. Ghirlando,et al.  Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. , 2001, The Journal of biological chemistry.

[15]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[16]  L. Simmons,et al.  Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. , 2002, Journal of immunological methods.

[17]  R. Huber,et al.  Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.

[18]  Bruce Tidor,et al.  Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors , 2008, Proceedings of the National Academy of Sciences.

[19]  Stephen P. Young,et al.  Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding* , 2001, The Journal of Biological Chemistry.

[20]  Huijuan Li,et al.  A high-throughput purification of monoclonal antibodies from glycoengineered Pichia pastoris. , 2010, Protein expression and purification.

[21]  S L Morrison,et al.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. , 1989, Journal of immunology.

[22]  Roy Jefferis,et al.  Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. , 2007, Journal of immunological methods.

[23]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[24]  M J Keen,et al.  Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. , 1995, Glycobiology.

[25]  Yoshiki Yamaguchi,et al.  Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. , 2006, Biochimica et biophysica acta.

[26]  R. Ionescu,et al.  Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. , 2010, Journal of chromatography. A.

[27]  S L Morrison,et al.  Effect of glycosylation on antibody function: implications for genetic engineering. , 1997, Trends in biotechnology.

[28]  R. Huber,et al.  The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. , 2000, Nature.

[29]  Robert Huber,et al.  The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex , 2000, Nature.

[30]  G. Winter,et al.  The binding site for C1q on IgG , 1988, Nature.

[31]  A K Patel,et al.  The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. , 1995, Molecular immunology.

[32]  H. Marques,et al.  FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. , 2008, Cancer genetics and cytogenetics.

[33]  J. Leoni,et al.  Structure of asymmetric non-precipitating antibody: presence of a carbohydrate residue in only one Fab region of the molecule. , 1986, Immunology.

[34]  A. West,et al.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. , 2001, Molecular cell.

[35]  D. James,et al.  Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro , 2005, Biotechnology progress.

[36]  Damian Houde,et al.  Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.

[37]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[38]  Kouhei Tsumoto,et al.  Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. , 2004, Journal of molecular biology.

[39]  M Goodall,et al.  The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. , 2000, Molecular immunology.

[40]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.